A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register

Bristol-Myers Squibb140,706 enrolled

Overview

The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) enrolled in the SRQ Register in Sweden.

Study Type

OBSERVATIONAL

Enrollment

140,706

Conditions

Rheumatoid Arthritis Psoriatic Arthritis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of RA or PsA * ≥18 years at index treatment initiation * Participants starting treatment with: * abatacept * non-targeted DMARDs * targeted DMARD Exclusion Criteria: \- Not applicable

Locations (1)

Local Institution

Princeton, New Jersey, United States

Outcomes

Primary Outcomes

Incidence Rate of Overall Malignancies

Time frame: 5 years

Incidence Rate of Melanoma

Time frame: 5 years

Incidence Rate of Non-melanoma Skin Cancer

Time frame: 5 years

Incidence Rate of Basal Cell Carcinoma

Time frame: 5 years

Incidence Rate of Squamous Cell Carcinoma

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.